SCHEMBL8136359

SCHEMBL8136359

C[C@@H](C(=O)O)c1cccc(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 6/20 0.59
PTGS2 P35354 5/20 0.59
MAPT P10636 3/20 0.59
CXCR1 P25024 2/20 0.59
CXCR2 P25025 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
SLC22A6 Q4U2R8 2/20 0.59
HIF1A Q16665 2/20 0.59
RECQL P46063 1/20 0.59
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP3A4 P08684 1/20 0.59
MAPK1 P28482 1/20 0.59
PMP22 Q01453 1/20 0.59
HSD17B10 Q99714 1/20 0.59
CXCL8 P10145 1/20 0.59
THPO P40225 1/20 0.59
AKR1C3 P42330 6/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8136361 1.00 PTGS1 (0.59) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL2183822 1.00 PTGS1 (0.59) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL18205086 0.98 PTGS1 (0.57) PTGS1PTGS2MAPTCXCR1CXCR2
Propionic Acid SCHEMBL28843580 0.92 PTGS1 (0.51) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL15695561 0.89 HDAC4 (0.51) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL7395276 0.86 HDAC4 (0.53) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL602096 0.86 PTGS2 (0.69) PTGS1PTGS2MAPTCXCR1CXCR2
Fluorobenzene SCHEMBL28140330 0.84 PTGS2 (0.62) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL8498061 0.83 HDAC4 (0.50) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL30631966 0.83 EPHX1 (0.50) HDAC4HDAC7HDAC5CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20140135520-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER Tokyo University of Science Educational Foundation Administration Organization (JP) 2014-05-15 US disclosed
EP-2719679-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER Tokyo University Of Science Educational Foundation Administrative Organization (JP) 2014-04-16 EP disclosed
CN-103209692-A Novel treatment of multiple sclerosis (MS) UNIV JW GOETHE FRANKFURT MAIN 2013-07-17 CN disclosed
US-6054456-A Substituted piperazine derivatives MERCK SHARP & DOHME LTD. (GB) 2000-04-25 US disclosed
WO-1997019943-A1 SUBSTITUTED PIPERAZINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135520-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER ALDH1A2, ADH1C, ADH1A PTGS1 2304/4885PTGS2 2021/4885MAPT 1725/4885
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM PTGS1 1305/4885PTGS2 1512/4885MAPT 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.